Advanced Search

Oncology & Hematology Coding Alert

ICD-10:

198.5's Combination Approach Sees a Change Under ICD-10

Published on Fri Aug 05, 2011

Be sure documentation clearly distinguishes bone from bone marrow metastases.ICD-10 will double your coding options for secondary neoplasms of bone and bone marrow.ICD-9: Under ICD-9 2011, you report 198.5 (Secondary malignant neoplasm of other specified sites; bone and bone marrow) to indicate the confirmed presence of cancer that has spread from a different (primary) site to the bones or bone marrow.ICD-10: The new code set, planned to take effect Oct. 1, 2013, instead may offer two distinct codes: C79.51, Secondary malignant neoplasm of bone C79.52, Secondary malignant neoplasm of bone marrow.Documentation: The switch to two separate codes means that clear confirmation of whether the bone or bone marrow is involved will be crucial to your ability to choose the proper ICD-10 code.Coder tip: Both ICD-9 and ICD-10 provide alternate codes for secondary neuroendocrine tumors. Under ICD- 9, you use 209.73 (Secondary neuroendocrine tumor of bone). ICD-10 includes C7B.03 (Secondary carcinoid [...]
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in your eNewsletter
  • 6 annual AAPC-approved CEUs*
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more
*CEUs available with select eNewsletters.

Other Articles in this issue of

Oncology & Hematology Coding Alert

View All